Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
Bettelli S, Marcheselli R, Pozzi S, Marcheselli L, Papotti R, Forti E, Cox MCC, Di Napoli A, Tadmor T, Mansueto GR, Musto P, Flenghi L, Quintini M, Galimberti S, Lalinga V, Donati V, Maiorana A, Polliack A, Sacchi S. Bettelli S, et al. Among authors: sacchi s. Leuk Res. 2021 May;104:106552. doi: 10.1016/j.leukres.2021.106552. Epub 2021 Feb 27. Leuk Res. 2021. PMID: 33689920 No abstract available.
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
Marcheselli R, Bari A, Tadmor T, Marcheselli L, Cox MC, Papotti R, Ferrari A, Baldini L, Gobbi P, Levy I, Pugliese G, Federico M, Polliack A, Pozzi S, Sacchi S. Marcheselli R, et al. Among authors: sacchi s. Hematol Oncol. 2020 Oct;38(4):439-445. doi: 10.1002/hon.2757. Epub 2020 Jun 17. Hematol Oncol. 2020. PMID: 32495944 Free PMC article.
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.
Bari A, Tadmor T, Sacchi S, Marcheselli L, Cox C, Liardo EV, Pozzi S, Benyamini N, Avivi I, Ferrari A, Baldini L, Falorio S, Gobbi P, Federico M, Polliack A. Bari A, et al. Among authors: sacchi s. Br J Haematol. 2014 Oct;167(1):133-6. doi: 10.1111/bjh.12930. Epub 2014 May 3. Br J Haematol. 2014. PMID: 24797533 Free article. No abstract available.
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Pozzi S, Gentile M, Sacchi S, Marcheselli R, Corso A, Cocito F, Musto P, Guarini A, Minoia C, Vincelli I, Ria R, Rivolti E, Mele G, Bari A, Mazzone C, Badiali S, Marcheselli L, Palumbo A, Morabito F. Pozzi S, et al. Among authors: sacchi s. Leuk Lymphoma. 2017 Mar;58(3):552-559. doi: 10.1080/10428194.2016.1205741. Epub 2016 Jul 21. Leuk Lymphoma. 2017. PMID: 27442600 Clinical Trial.
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.
Marcheselli R, Franceschetto A, Sacchi S, Bari A, Levy I, Pizzichini P, Prosperi D, D'Apollo R, Massi L, Casolo A, Pozzi S, Marcheselli L, Tadmor T, Prandini N, Cox MC. Marcheselli R, et al. Among authors: sacchi s. Leuk Lymphoma. 2019 Aug;60(8):1958-1964. doi: 10.1080/10428194.2018.1564049. Epub 2019 Jan 28. Leuk Lymphoma. 2019. PMID: 30689474 Free article.
341 results